Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interleukin 7 - Revimmune SAS

Drug Profile

Interleukin 7 - Revimmune SAS

Alternative Names: CYT 107; Glycosylated recombinant human interleukin-7 - Cytheris; IL-7; Recombinant human interleukin-7 - Cytheris; rhIL-7; Second-generation CYT 99 007

Latest Information Update: 10 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytheris
  • Developer Cognate BioServices; Cytheris; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Revimmune SAS; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The French National Agency for Research on AIDS and Viral Hepatitis; University Hospital Limoges
  • Class Antineoplastics; Antivirals; Cytokines; Interleukins; Recombinant proteins
  • Mechanism of Action Interleukin 7 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Colorectal cancer; HIV infections; Prostate cancer; Sepsis
  • Suspended Idiopathic CD4-positive T-lymphocytopenia
  • Discontinued Bone marrow transplant rejection; Hepatitis B; Hepatitis C; Progressive multifocal leukoencephalopathy

Most Recent Events

  • 08 Nov 2019 Revimmune plans a phase II trial for Nontuberculous mycobacterium infection in January 2020 (NCT04154826)
  • 01 Jun 2019 Phase-II clinical trials in Sepsis in USA and France (IV) (NCT03821038)
  • 29 Jan 2019 Revimmune plans the IRIS-7-C&D phase II trial for Sepsis in March 2019 (NCT03821038)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top